AbCellera Biologics (ABCL) Other Non Operating Income (2020 - 2026)

AbCellera Biologics (ABCL) has 7 years of Other Non Operating Income data on file, last reported at $4.3 million in Q1 2026.

• Quarterly Other Non Operating Income rose 4.48% year-over-year to $4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.5 million (up 89.47% YoY) and the FY2025 annual result came in at -$2.7 million, down 119.9% from the prior year.
• Other Non Operating Income grew to $4.3 million in Q1 2026, from -$13.3 million in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $10.8 million in Q4 2022 to a low of -$34.9 million in Q4 2024.
• A 5-year average of $403176.5 and a median of $3.4 million in 2023 frame the typical range for Other Non Operating Income.
• Annual changes were most pronounced in 2023 — Other Non Operating Income jumped 418.0% — and 2024, when it plunged 1135.07%.
• Tracing ABCL's Other Non Operating Income over 5 years: stood at $10.8 million in 2022, then tumbled by 68.8% to $3.4 million in 2023, then sank by 1135.07% to -$34.9 million in 2024, then jumped by 61.98% to -$13.3 million in 2025, then jumped by 132.66% to $4.3 million in 2026.
• The last three Other Non Operating Income figures came in at $4.3 million (Q1 2026), -$13.3 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.